Gilead, Kite shorten Yescarta manufacturing by two days in ‘incremental’ improvement

Gilead and Kite announced Tuesday it received FDA approval to shorten its manufacturing process for the cell therapy Yescarta, a move expected to reduce the time patients need to wait for the treatment by two days.

The shortening, measured by what’s known as “median turnaround time…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks